Crossref
A Fixed-Duration Bispecific Antibody Strategy for Treatment of Multiple Myeloma
Advances in Oncology · 2026-05 · 6 (1) · 129-144
DOI: 10.1016/j.yao.2026.02.003 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advances in Oncology, 2026-05. Verfasst von Yetunde Ogunsesan und 3 weiteren Autor:innen. Die Arbeit nennt 82 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Ogunsesan, Y., Shah, R. K., Shah, M. R., & Mohan, M. (2026). A Fixed-Duration Bispecific Antibody Strategy for Treatment of Multiple Myeloma. Advances in Oncology, 6(1), 129-144. https://doi.org/10.1016/j.yao.2026.02.003
Vancouver
Ogunsesan Y, Shah RK, Shah MR, Mohan M. A Fixed-Duration Bispecific Antibody Strategy for Treatment of Multiple Myeloma. Advances in Oncology. 2026;6(1):129-144. doi:10.1016/j.yao.2026.02.003
BibTeX
@article{Ogunsesan2026,
author = {Ogunsesan, Yetunde and Shah, Ravi K. and Shah, Mansi R. and Mohan, Meera},
title = {A Fixed-Duration Bispecific Antibody Strategy for Treatment of Multiple Myeloma},
journal = {Advances in Oncology},
year = {2026},
volume = {6},
number = {1},
pages = {129--144},
doi = {10.1016/j.yao.2026.02.003}
}
EUVIMED